General Research
Model: human
Pilot study of H-2 therapy in Parkinson’s disease: A randomized double-blind placebo-controlled trial
Simplified Version Available
Hydrogen Therapy for Parkinson's Disease: A Promising New Approach
A pilot study on hydrogen therapy for Parkinson's disease found that participants who received hydrogen-rich water showed significant improvements in their symptoms. Hydrogen therapy may be a promising new approach for managing Parkinson's disease and other conditions related to oxidative stress. More research is needed, but the findings are encouraging and suggest a potential new treatment option.
Read Simplified ArticleAbstract
Publish Year 2013 Country Japan Rank Positive Journal Movement Disorders Primary Topic Brain Secondary TopicParkinson's Disease Model Human Tertiary TopicOxidative Stress Vehicle Water (Dissolved) pH Neutral Application Ingestion Comparison Complement Levodopa
Background
Methods: In this a placebo-controlled, randomized, double-blind, parallel-group clinical pilot study, the authors assessed the efficacy of H₂ -water in Japanese patients with levodopa-medicated PD. Participants drank 1,000 mL/day of H₂-water or pseudo water for 48 weeks.
Methods
Results: Total Unified Parkinson's Disease Rating Scale (UPDRS) scores in the H₂-water group (n=9) improved (median, -1.0; mean ± standard deviation, -5.7 ± 8.4), whereas UPDRS scores in the placebo group (n=8) worsened (median, 4.5; mean ± standard deviation, 4.1 ± 9.2). Despite the minimal number of patients and the short duration of the trial, the difference was significant (P<0.05). Conclusions: The results indicated that drinking H₂-water was safe and well tolerated, and a significant improvement in total UPDRS scores for patients in the H₂-water group was demonstrated.